Lineage Cell Therapeutics, Inc. Annual Income Tax Expense (Benefit) in USD from 2018 to 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
Summary
Lineage Cell Therapeutics, Inc. quarterly/annual Income Tax Expense (Benefit) history and growth rate from 2018 to 2023.
  • Lineage Cell Therapeutics, Inc. Income Tax Expense (Benefit) for the quarter ending June 30, 2024 was $0.000.
  • Lineage Cell Therapeutics, Inc. annual Income Tax Expense (Benefit) for 2023 was -$1.8M, a 433% decline from 2022.
  • Lineage Cell Therapeutics, Inc. annual Income Tax Expense (Benefit) for 2022 was $541K.
  • Lineage Cell Therapeutics, Inc. annual Income Tax Expense (Benefit) for 2020 was -$1.24M, a 83.3% increase from 2019.
Income Tax Expense (Benefit), Annual (USD)
Income Tax Expense (Benefit), YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 -$1.8M -$2.34M -433% Jan 1, 2023 Dec 31, 2023 10-K 2024-03-07
2022 $541K Jan 1, 2022 Dec 31, 2022 10-K 2024-03-07
2020 -$1.24M +$6.17M +83.3% Jan 1, 2020 Dec 31, 2020 10-K 2022-03-10
2019 -$7.41M -$7.75M -2241% Jan 1, 2019 Dec 31, 2019 10-K 2021-03-11
2018 $346K Jan 1, 2018 Dec 31, 2018 10-K 2020-03-12
* An asterisk sign (*) next to the value indicates that the value is likely invalid.